Cordycepin inhibits the process of developing new blood vessels (angiogenesis). Research has shown that cordycepin has significant properties on angiogenesis and tumor growth, thus it could be a good candidate for diseases associated with angiogenesis, such as arteriosclerosis, myocardial infarction, limb ischemia, retinopathies, benign and malignant angiogenic tumors.
Nan JX, Park EJ, Yang BK, Song CH, Ko G, Sohn DH (2001). Antifibrotic effect of extracellular biopolymer from submerged mycelial cultures of Cordyceps militaris on liver fibrosis induced by bile duct ligation and scission in rats. Arch. Pharm. Res. 24(4):327–32. (Read abstract)
Yoo HS, Shin JW, Cho JH, Son CG, Lee YW, Park SY, et al (2004). Effects of Cordyceps militaris extract on angiogenesis and tumor growth. Acta Pharmacol. Sin., 25:657–65. (Read abstract)
Cho HJ, Cho JY, Rhee MH, Park HJ (2007). Cordycepin (3’- deoxyadenosine) inhibits human platelet aggregation in a cyclic AMP- and cyclic GMP-dependent manner. Eur. J. Pharmacol., 558:43–51. (Read Full Paper)
Park E-S, Kang D-H, Yang M-K et al (2014). “Cordycepin, 3-deoxyadenosine, prevents rat hearts from ischemia/reperfusion injury via activation of Akt/GSK-3𝛽/p70S6K signaling pathway and HO-1 expression”. Cardiovascular Toxicology, 14(1):1–9. (Read abstract)
Tabrizchi R, Bedi S. (2001). Pharmacology of adenosine receptors in the vasculature. Pharmacol. Ther., 91:133–47. (Read abstract)
Choi DB, Cha WS, Park N, et al. (2011). Purification and characterization of a novel fibrinolytic enzyme from fruiting bodies of Korean Cordyceps militaris. Bioresource Technol., 102:3279–85. (Read abstract)